醫藥中間體市場規模、佔有率及成長分析（依產品、類別、應用、最終用戶及地區分類）－2026-2033年產業預測

預計到 2024 年，醫藥中間體市場規模將達到 392.3 億美元，到 2025 年將達到 417.3 億美元，到 2033 年將達到 683.9 億美元，在預測期（2026-2033 年）內，複合年成長率為 6.37%。

醫藥中間體市場在原料藥藥物成分（API）的生產中扮演著至關重要的角色，尤其是在合成過程中API的形成。這些中間體通常來自煤焦油和石油等優質基礎成分，並在製藥和化妝品行業中有著廣泛的應用。市場成長的驅動力來自對API日益成長的需求，而API需求的成長又受到先進治療方法和個人化醫療趨勢的推動。然而，生物製藥的高成本以及API生產所需的大量資本投入等挑戰可能會限制其成長潛力。儘管如此，製造技術的進步以及研發投入的增加預計將在不久的將來為醫藥中間體市場帶來巨大的機遇，並鞏固其市場格局。

醫藥中間體市場促進因素

慢性病盛行率的上升以及全球人口老化，顯著推動了用於慢性病治療藥物製劑的醫藥中間體需求的成長。隨著包括糖尿病在內的慢性病患者人數的不斷增加，醫療保健產業迫切需要開發有效的治療方法。鑑於慢性病影響相當大比例的人口，顯然，對創新藥物解決方案的需求龐大。這些趨勢正在推動中間體市場的成長，以滿足不斷成長的需求。

醫藥中間體市場的限制

生物製藥的高昂採購成本對全球醫藥中間體市場的發展構成重大挑戰。此外，活性藥物成分（API）生產所需的大量資本投入也阻礙了市場擴張。這些財務壁壘對各相關人員帶來障礙，並可能限制其在產業內進行創新和有效競爭的能力。因此，醫藥中間體市場的整體成長軌跡可能受到不利影響，從而限制新參與企業和現有企業的發展機會。解決這些經濟限制因素對於創造更穩健的市場環境至關重要。

醫藥中間體市場趨勢

醫藥中間體市場的一個顯著趨勢是慢性心血管疾病盛行率的不斷上升，這給全球醫療保健帶來了沉重負擔。人們對心臟衰竭和缺血性心臟疾病等心臟疾病日益關注，推動了對創新醫學中間體的需求，這些中間體有助於開發有效的治療方法。由於缺血性心臟疾病影響全球數百萬人，製藥公司正在加大研發投入，以生產能夠提高藥物療效和安全性的專用中間體。這種激增的需求為製造商創造了盈利機會，同時也凸顯了推動醫藥技術發展以應對與心血管疾病相關的日益嚴峻的醫療保健挑戰的重要性。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管分析
• 專利分析
• 案例研究分析

全球醫藥中間體市場規模（依產品及複合年成長率分類）（2026-2033 年）

• 化學中間體
• 醫藥原料中間體
• 掌性中間體
• 非掌性中間體
• 客製化中間體

全球醫藥中間體市場規模（依類別分類）及複合年成長率（2026-2033 年）

• 品牌醫藥中間體
• 學名藥中間體

全球醫藥中間體市場規模（按應用及複合年成長率分類）（2026-2033 年）

• 止痛藥
• 抗發炎藥
• 循環系統藥物
• 抗糖尿病藥物
• 抗生素
• 抗癌藥物
• 其他

全球醫藥中間體市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）

• 生物技術和製藥公司
• 研究所
• CMOS／CROS

全球醫藥中間體市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2021-2023年營收年比比較

主要企業簡介

• BASF SE（Germany）
• Sanofi SA（France）
• Thermo Fisher Scientific Inc.（US）
• Merck KGaA（Germany）
• Dishman Carbogen Amcis Ltd.（India）
• Evonik Industries AG（Germany）
• Arkema Inc.（France）
• Lonza Group AG（Switzerland）
• Wuxi AppTec Co., Ltd.（China）
• Aurobindo Pharma Limited（India）
• Lianhe Chemical Technology Co., Ltd.（China）
• Cambrex Corporation（US）
• Vertellus Holdings LLC（US）
• Hovione LLC（Portugal）
• Hikal Ltd.（India）
• Codexis Inc.（US）
• Aceto Corporation（US）
• Interchem Corporation（US）
• Midas Pharma GmbH（Germany）
• Arbiom（US）

結論與建議

Pharmaceutical Intermediates Market size was valued at USD 39.23 Billion in 2024 and is poised to grow from USD 41.73 Billion in 2025 to USD 68.39 Billion by 2033, growing at a CAGR of 6.37% during the forecast period (2026-2033).

The pharmaceutical intermediates market plays a crucial role as raw materials in the production of bulk drugs, particularly in forming active pharmaceutical ingredients (APIs) during synthesis. These intermediates, often derived from high-quality basic components like coal tar and petroleum, find extensive application in both pharmaceutical and cosmetic sectors. The market is driven by rising demand for APIs, fueled by trends in advanced therapies and personalized medicine. However, challenges such as high costs of biopharmaceutical drugs and significant capital investments for API production may limit growth potential. Nevertheless, advancements in manufacturing technologies and increased investment in research and development are set to unlock substantial opportunities, enhancing the market landscape for pharmaceutical intermediates in the near future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Pharmaceutical Intermediates market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Pharmaceutical Intermediates Market Segments Analysis

Global Pharmaceutical Intermediates Market is segmented by product, category, application, end user and region. Based on product, the market is segmented into chemical intermediates, bulk drug intermediates, chiral intermediates, achiral intermediates and custom intermediates. Based on category, the market is segmented into branded drug intermediates and generic drug intermediates. Based on application, the market is segmented into analgesics, anti-inflammatory drug, cardiovascular drugs, anti-diabetic drugs, antimicrobial drugs, anti-cancer drugs and others. Based on end user, the market is segmented into biotech and pharma companies, research laboratory and CMOS/CROS. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Pharmaceutical Intermediates Market

The rising prevalence of chronic diseases, coupled with a growing elderly population around the globe, significantly contributes to the escalating demand for pharmaceutical intermediates used in drug formulations for chronic disease management. As more individuals are diagnosed with conditions such as diabetes and other chronic ailments, the healthcare sector faces increasing pressure to develop effective treatment options. This trend highlights the urgent need for innovative pharmaceutical solutions, as a substantial portion of the population is affected by chronic illnesses. Consequently, these dynamics are propelling the growth of the pharmaceutical intermediates market to meet this rising demand.

Restraints in the Pharmaceutical Intermediates Market

The significant expenses tied to acquiring biopharmaceutical drugs present a considerable challenge for the advancement of the global pharmaceutical intermediates market. Additionally, the substantial capital investments necessary for the manufacturing of active pharmaceutical ingredients (APIs) further hinder market expansion. These financial barriers create obstacles for various stakeholders, potentially limiting their ability to innovate and compete effectively within the industry. As a result, the overall growth trajectory of the pharmaceutical intermediates market may be adversely affected, restricting opportunities for new entrants and established companies alike. Addressing these economic constraints will be crucial for promoting a more robust market environment.

Market Trends of the Pharmaceutical Intermediates Market

A notable trend in the pharmaceutical intermediates market is the escalating prevalence of chronic cardiovascular diseases, which significantly strains global healthcare systems. Growing concerns over heart conditions like heart failure and ischemic heart disease drive demand for innovative pharmaceutical intermediates that facilitate the development of effective treatments. As ischemic heart disease affects millions worldwide, pharmaceutical companies are increasingly investing in research and development to produce specialized intermediates that enhance drug efficacy and safety. This burgeoning demand presents lucrative opportunities for manufacturers while underscoring the importance of advancements in pharmaceutical technologies to address escalating healthcare challenges associated with cardiovascular diseases.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Patent Analysis
• Case Study Analysis

Global Pharmaceutical Intermediates Market Size by Product & CAGR (2026-2033)

• Market Overview
• Chemical Intermediates
• Bulk Drug Intermediates
• Chiral Intermediates
• Achiral Intermediates
• Custom Intermediates

Global Pharmaceutical Intermediates Market Size by Category & CAGR (2026-2033)

• Market Overview
• Branded Drug Intermediates
• Generic Drug Intermediates

Global Pharmaceutical Intermediates Market Size by Application & CAGR (2026-2033)

• Market Overview
• Analgesics
• Anti-Inflammatory Drug
• Cardiovascular Drugs
• Anti-Diabetic Drugs
• Antimicrobial Drugs
• Anti-Cancer Drugs
• Others

Global Pharmaceutical Intermediates Market Size by End User & CAGR (2026-2033)

• Market Overview
• Biotech And Pharma Companies
• Research Laboratory
• CMOS/CROS

Global Pharmaceutical Intermediates Market Size & CAGR (2026-2033)

• North America (Product, Category, Application, End User)
  • USA
  • Canada
• Europe (Product, Category, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Category, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Category, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Category, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• BASF SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dishman Carbogen Amcis Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evonik Industries AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arkema Inc. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wuxi AppTec Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lianhe Chemical Technology Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cambrex Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertellus Holdings LLC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hovione LLC (Portugal)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikal Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Codexis Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aceto Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Interchem Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Midas Pharma GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arbiom (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations